SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: sjemmeri who wrote (4445)8/5/2005 11:56:41 AM
From: scaram(o)ucheRead Replies (1) of 4974
 
>> That the co raised the size of this deal to 6.4 mln shares from 4.5 mln explains some of the weak pricing here. However, it is still weak despite 1) the likelihood that the co's first drug will be licensed from Abbott and 2) the Biotech Index being up 28% since early April and near a new 52-week high. Looks like there is little appetite for development-stage biotech deals. <<

companies try to run through a window, and find that the v.c. structure fits the bubble mind, not real-world. big reverse splits, down rounds...... it's healthy to see people scramble just to get 50% back. it's even better to see insiders like the Cyclis gang, settling for a fraction after an ugly dump.

so, I see it quite differently, but the same.

:-)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News